Optimization of Cyclic Plasmin Inhibitors: From Benzamidines to Benzylamines

Journal of Medicinal Chemistry

Volumn 59, Issue 13, 2016, Pages 6370-6386

  Hinkes, Stefan ^a   Wuttke, André ^a   Saupe, Sebastian M ^a   Ivanova, Teodora ^a   Wagner, Sebastian ^a   Knörlein, Anna ^a   Heine, Andreas ^a   Klebe, Gerhard ^a   Steinmetzer, Torsten ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; ANTIFIBRINOLYTIC AGENT; APROTININ; BENZAMIDINE DERIVATIVE; BENZYLAMINE DERIVATIVE; DIAMINE DERIVATIVE; N (4 CARBAMIMIDOYLBENZYL) 14 [(N CYCLOHEXYLSULFAMOYL)AMINO] 3,7,13 TRIOXO 2,8,12 TRIAZA 5(1,4) PIPERAZINA 1,9(1,4) DIBENZENACYCLOPENTADECAPHANE 11 CARBOXAMIDE; N (4 CARBAMIMIDOYLBENZYL) 16 [(N CYCLOHEXYLSULFAMOYL)AMINO] 3,9,15 TRIOXO 2,10,14 TRIAZA 6(1,4) PIPERAZINA 1,11(1,4) DIBENZENACYCLOHEPTADECAPHANE 13 CARBOXAMIDE; N (4 CARBAMIMIDOYLBENZYL) 3,7,13 TRIOXO 14 (3 PHENYLPROPANAMIDO) 2,8,12 TRIAZA 5(1,4) PIPERAZINA 1,9(1,4) DIBENZENACYCLOPENTADECAPHANE 11 CARBOXAMIDE; N (4 CARBAMIMIDOYLBENZYL) 3,9,15 TRIOXO 16 (3 PHENYLPROPANAMIDO) 2,10,14 TRIAZA 6(1,4) PIPERAZINA 1,11(1,4) DIBENZENACYCLOHEPTADECAPHANE 13 CARBOXAMIDE; N [4 (AMINOMETHYL)BENZYL] 16 [(N CYCLOHEXYLSULFAMOYL)AMINO] 3,9,15 TRIOXO 2,10,14 TRIAZA 6(1,4) PIPERAZINA 1,11(1,4) DIBENZENACYCLOHEPTADECAPHANE 13 CARBOXAMIDE; N [4 (AMINOMETHYL)BENZYL] 3,9,15 TRIOXO (16 PHENYL SULFONAMIDO) 2,10,14 TRIAZA 6(1,4) PIPERAZINA 1,11(1,4) DIBENZENACYCLOHEPTADECAPHANE 13 CARBOXAMIDE; PLASMIN; PLASMIN INHIBITOR; TRYPSIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYCLIZATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME KINETICS; FIBRINOLYSIS; HEMOSTASIS; HUMAN; PLASMA; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; METABOLISM; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTIFIBRINOLYTIC AGENTS; BENZAMIDINES; BENZYLAMINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYSIN; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84978765403     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00606     Document Type: Article

References (50)

1. Draxler, D. F.; Medcalf, R. L. The fibrinolytic system-more than fibrinolysis? Transfus. Med. Rev. 2015, 29, 102-109 10.1016/j.tmrv.2014.09.006
2. Castellino, F. J.; Ploplis, V. A. Structure and function of the plasminogen/plasmin system Thromb. Haemostasis 2005, 93, 647-654 10.1160/TH04-12-0842
3. Deryugina, E. I.; Quigley, J. P. Cell surface remodeling by plasmin: a new function for an old enzyme J. Biomed. Biotechnol. 2012, 2012, 564259 10.1155/2012/564259
4. Swedberg, J. E.; Harris, J. M. Natural and engineered plasmin inhibitors: applications and design strategies ChemBioChem 2012, 13, 336-348 10.1002/cbic.201100673
5. Munakata, S.; Tashiro, Y.; Nishida, C.; Sato, A.; Komiyama, H.; Shimazu, H.; Dhahri, D.; Salama, Y.; Eiamboonsert, S.; Takeda, K.; Yagita, H.; Tsuda, Y.; Okada, Y.; Nakauchi, H.; Sakamoto, K.; Heissig, B.; Hattori, K. Inhibition of plasmin protects against colitis in mice by suppressing matrix metalloproteinase 9-mediated cytokine release from myeloid cells Gastroenterology 2015, 148, 565-578 10.1053/j.gastro.2014.12.001
6. Sato, A.; Nishida, C.; Sato-Kusubata, K.; Ishihara, M.; Tashiro, Y.; Gritli, I.; Shimazu, H.; Munakata, S.; Yagita, H.; Okumura, K.; Tsuda, Y.; Okada, Y.; Tojo, A.; Nakauchi, H.; Takahashi, S.; Heissig, B.; Hattori, K. Inhibition of plasmin attenuates murine acute graft-versus-host disease mortality by suppressing the matrix metalloproteinase-9-dependent inflammatory cytokine storm and effector cell trafficking Leukemia 2015, 29, 145-156 10.1038/leu.2014.151
7. Phipps, K. D.; Surette, A. P.; O'Connell, P. A.; Waisman, D. M. Plasminogen receptor S100A10 is essential for the migration of tumor-promoting macrophages into tumor sites Cancer Res. 2011, 71, 6676-6683 10.1158/0008-5472.CAN-11-1748
8. Ishihara, M.; Nishida, C.; Tashiro, Y.; Gritli, I.; Rosenkvist, J.; Koizumi, M.; Okaji, Y.; Yamamoto, R.; Yagita, H.; Okumura, K.; Nishikori, M.; Wanaka, K.; Tsuda, Y.; Okada, Y.; Nakauchi, H.; Heissig, B.; Hattori, K. Plasmin inhibitor reduces T-cell lymphoid tumor growth by suppressing matrix metalloproteinase-9-dependent CD11b(+)/F4/80(+) myeloid cell recruitment Leukemia 2012, 26, 332-339 10.1038/leu.2011.203
9. Voegeli, R.; Rawlings, A. V.; Breternitz, M.; Doppler, S.; Schreier, T.; Fluhr, J. W. Increased stratum corneum serine protease activity in acute eczematous atopic skin Br. J. Dermatol. 2009, 161, 70-77 10.1111/j.1365-2133.2009.09142.x
10. Rawlings, A. V.; Voegeli, R. Stratum corneum proteases and dry skin conditions Cell Tissue Res. 2013, 351, 217-235 10.1007/s00441-012-1501-x
11. Levy, J. H. Pharmacologic methods to reduce perioperative bleeding Transfusion 2008, 48, 31s-38s 10.1111/j.1537-2995.2007.01574.x
12. Johansson, P. I.; Ostrowski, S. R.; Secher, N. H. Management of major blood loss: an update Acta Anaesthesiol. Scand. 2010, 54, 1039-1049 10.1111/j.1399-6576.2010.02265.x
13. Mannucci, P. M.; Levi, M. Prevention and treatment of major blood loss N. Engl. J. Med. 2007, 356, 2301-2311 10.1056/NEJMra067742
14. Schneeweiss, S.; Seeger, J. D.; Landon, J.; Walker, A. M. Aprotinin during coronary-artery bypass grafting and risk of death N. Engl. J. Med. 2008, 358, 771-783 10.1056/NEJMoa0707571
15. Murkin, J. M.; Falter, F.; Granton, J.; Young, B.; Burt, C.; Chu, M. High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients Anesth. Analg. 2010, 110, 350-353 10.1213/ANE.0b013e3181c92b23
16. Sander, M.; Spies, C. D.; Martiny, V.; Rosenthal, C.; Wernecke, K. D.; von Heymann, C. Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis Crit. Care 2010, 14, R148 10.1186/cc9216
17. Cheng, L.; Pettersen, D.; Ohlsson, B.; Schell, P.; Karle, M.; Evertsson, E.; Pahlen, S.; Jonforsen, M.; Plowright, A. T.; Bostrom, J.; Fex, T.; Thelin, A.; Hilgendorf, C.; Xue, Y.; Wahlund, G.; Lindberg, W.; Larsson, L. O.; Gustafsson, D. Discovery of the fibrinolysis inhibitor AZD6564, acting via interference of a protein-protein interaction ACS Med. Chem. Lett. 2014, 5, 538-543 10.1021/ml400526d
18. Al-Horani, R. A.; Desai, U. R. Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders Med. Res. Rev. 2014, 34, 1168-1216 10.1002/med.21315
19. Swedberg, J. E.; Harris, J. M. Plasmin substrate binding site cooperativity guides the design of potent peptide aldehyde inhibitors Biochemistry 2011, 50, 8454-8462 10.1021/bi201203y
20. Okada, Y.; Tsuda, Y.; Tada, M.; Wanaka, K.; Okamoto, U.; Hijikata-Okunomiya, A.; Okamoto, S. Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship Chem. Pharm. Bull. 2000, 48, 1964-1972 10.1248/cpb.48.1964
21. Tsuda, Y.; Tada, M.; Wanaka, K.; Okamoto, U.; Hijikata-Okunomiya, A.; Okamoto, S.; Okada, Y. Structure-inhibitory activity relationship of plasmin and plasma kallikrein inhibitors Chem. Pharm. Bull. 2001, 49, 1457-1463 10.1248/cpb.49.1457
22. Hidaka, K.; Gohda, K.; Teno, N.; Wanaka, K.; Tsuda, Y. Active site-directed plasmin inhibitors: Extension on the P2 residue Bioorg. Med. Chem. 2016, 24, 545-553 10.1016/j.bmc.2015.12.009
23. Markwardt, F.; Landmann, H.; Walsmann, P. Comparative studies on the inhibition of trypsin, plasmin, and thrombin by derivatives of benzylamine and benzamidine Eur. J. Biochem. 1968, 6, 502-506 10.1111/j.1432-1033.1968.tb00473.x
24. Alves, N. J.; Kline, J. A. Comparative study on the inhibition of plasmin and delta-plasmin via benzamidine derivatives Biochem. Biophys. Res. Commun. 2015, 457, 358-362 10.1016/j.bbrc.2014.12.117
25. Dietrich, W.; Nicklisch, S.; Koster, A.; Spannagl, M.; Giersiefen, H.; van de Locht, A. CU-2010-a novel small molecule protease inhibitor with antifibrinolytic and anticoagulant properties Anesthesiology 2009, 110, 123-130 10.1097/ALN.0b013e318191408c
26. Saupe, S. M.; Steinmetzer, T. A new strategy for the development of highly potent and selective plasmin inhibitors J. Med. Chem. 2012, 55, 1171-1180 10.1021/jm2011996
27. Saupe, S. M.; Leubner, S.; Betz, M.; Klebe, G.; Steinmetzer, T. Development of new cyclic plasmin inhibitors with excellent potency and selectivity J. Med. Chem. 2013, 56, 820-831 10.1021/jm3012917
28. Morrison, J. The slow-binding and slow, tight-binding inhibition of enzyme-catalysed reactions Trends Biochem. Sci. 1982, 7, 102-105 10.1016/0968-0004(82)90157-8
29. Tucker, T. J.; Lumma, W. C.; Mulichak, A. M.; Chen, Z.; Naylor-Olsen, A. M.; Lewis, S. D.; Lucas, R.; Freidinger, R. M.; Kuo, L. C. Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site J. Med. Chem. 1997, 40, 830-832 10.1021/jm960762y
30. Steinmetzer, T.; Stürzebecher, J.; Schuster, O.; Stürzebecher, U.; Schweinitz, A.; Stürzebecher, A. New substrate analogue inhibitors of factor Xa containing 4-amidinobenzylamide as P1 residue: part 1 Med. Chem. 2006, 2, 349-361 10.2174/157340606777724040
31. Schweinitz, A.; Steinmetzer, T.; Banke, I. J.; Arlt, M. J.; Stürzebecher, A.; Schuster, O.; Geissler, A.; Giersiefen, H.; Zeslawska, E.; Jacob, U.; Krüger, A.; Stürzebecher, J. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents J. Biol. Chem. 2004, 279, 33613-33622 10.1074/jbc.M314151200
32. Bajusz, S.; Szell, E.; Barabas, E.; Bagdy, D. Design and synthesis of peptide inhibitors of blood coagulations Folia Haematol. Int. Mag. Klin. Morphol. Blutforsch. 1982, 109, 16-21
33. Wiley, M. R.; Chirgadze, N. Y.; Clawson, D. K.; Craft, T. J.; Giffordmoore, D. S.; Jones, N. D.; Olkowski, J. L.; Schacht, A. L.; Weir, L. C.; Smith, G. F. Serine-protease selectivity of the thrombin inhibitor D-Phe-Pro-Agmatine and its homologs Bioorg. Med. Chem. Lett. 1995, 5, 2835-2840 10.1016/0960-894X(95)00496-G
34. Lee, K.; Jung, W. H.; Park, C. W.; Hong, C. Y.; Kim, I. C.; Kim, S.; Oh, Y. S.; Kwon, O. H.; Lee, S. H.; Park, H. D.; Kim, S. W.; Lee, Y. H.; Yoo, Y. J. Benzylamine-based selective and orally bioavailable inhibitors of thrombin Bioorg. Med. Chem. Lett. 1998, 8, 2563-2568 10.1016/S0960-894X(98)00456-9
35. Rittle, K. E.; Barrow, J. C.; Cutrona, K. J.; Glass, K. L.; Krueger, J. A.; Kuo, L. C.; Lewis, S. D.; Lucas, B. J.; McMasters, D. R.; Morrissette, M. M.; Nantermet, P. G.; Newton, C. L.; Sanders, W. M.; Yan, Y.; Vacca, J. P.; Selnick, H. G. Unexpected enhancement of thrombin inhibitor potency with o-aminoalkylbenzylamides in the P1 position Bioorg. Med. Chem. Lett. 2003, 13, 3477-3482 10.1016/S0960-894X(03)00732-7
36. Steinmetzer, T.; Dönnecke, D.; Korsonewski, M.; Neuwirth, C.; Steinmetzer, P.; Schulze, A.; Saupe, S. M.; Schweinitz, A. Modification of the N-terminal sulfonyl residue in 3-amidinophenylalanine-based matriptase inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 67-73 10.1016/j.bmcl.2008.11.019
37. Sperzel, M.; Huetter, J. Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation J. Thromb. Haemostasis 2007, 5, 2113-2118 10.1111/j.1538-7836.2007.02717.x
38. Huggins, D. J.; Sherman, W.; Tidor, B. Rational approaches to improving selectivity in drug design J. Med. Chem. 2012, 55, 1424-1444 10.1021/jm2010332
39. Künzel, S.; Schweinitz, A.; Reissmann, S.; Stürzebecher, J.; Steinmetzer, T. 4-amidinobenzylamine-based inhibitors of urokinase Bioorg. Med. Chem. Lett. 2002, 12, 645-648 10.1016/S0960-894X(01)00815-0
40. Cederholm-Williams, S. A. Concentration of plasminogen and antiplasmin in plasma and serum J. Clin. Pathol. 1981, 34, 979-981 10.1136/jcp.34.9.979
41. Royston, D. High-dose aprotinin therapy: a review of the first five years' experience J. Cardiothorac. Vasc. Anesth. 1992, 6, 76-100 10.1016/1053-0770(91)90052-U
42. Zhu, B. Y.; Jia, Z. J.; Zhang, P.; Su, T.; Huang, W.; Goldman, E.; Tumas, D.; Kadambi, V.; Eddy, P.; Sinha, U.; Scarborough, R. M.; Song, Y. Inhibitory effect of carboxylic acid group on hERG binding Bioorg. Med. Chem. Lett. 2006, 16, 5507-5512 10.1016/j.bmcl.2006.08.039
43. Kaiser, B.; Hauptmann, J.; Markwardt, F. The pharmacodynamics of synthetic thrombin inhibitors of the basic type substituted n-alpha arylsulfonylated phenylalanine amide Pharmazie 1987, 42, 119-121
44. Peternel, L.; Stempelj, M.; Cerne, M.; Zega, A.; Obreza, A.; Oblak, M.; Drevensek, G.; Budihna, M. V.; Stanovnik, L.; Urleb, U. Direct thrombin inhibitors built on the azaphenylalanine scaffold provoke degranulation of mast cells Thromb. Haemostasis 2006, 95, 294-300 10.1160/TH05-10-0683
45. Kloek, J. A.; Leschinsky, K. L. An improved synthesis of sulfamoyl chlorides J. Org. Chem. 1976, 41, 4028-4029 10.1021/jo00887a022
46. Iványi, T.; Lázár, I. Synthesis and in vitro enzyme hydrolysis of trioxadiaza- and tetraoxadiaza-crown ether-based complexing agents with disposable ester pendant arms Synthesis 2005, 2005, 3555-3564 10.1055/s-2005-918442
47. Meyer, D.; Sielaff, F.; Hammami, M.; Böttcher-Friebertshäuser, E.; Garten, W.; Steinmetzer, T. Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation Biochem. J. 2013, 452, 331-343 10.1042/BJ20130101
48. Walsmann, P. On the purification of thrombin preparations Pharmazie 1968, 23, 401-402
49. Stein, R. L.; Strimpler, A. M.; Edwards, P. D.; Lewis, J. J.; Mauger, R. C.; Schwartz, J. A.; Stein, M. M.; Trainor, D. A.; Wildonger, R. A.; Zottola, M. A. Mechanism of slow-binding inhibition of human leukocyte elastase by trifluoromethyl ketones Biochemistry 1987, 26, 2682-2689 10.1021/bi00384a005
50. Maiwald, A.; Hammami, M.; Wagner, S.; Heine, A.; Klebe, G.; Steinmetzer, T. Changing the selectivity profile-from substrate analog inhibitors of thrombin and factor Xa to potent matriptase inhibitors. J. Enzyme Inhib. Med. Chem. 2016, DOI: 10.3109/14756366.2016.1172574.